ArticleAACE endocrinology and diabetes
Efficacy and Safety of Once-Weekly IcoSema in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.Cardiovascular diabetology. Endocrinology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effectiveness and safety of once-weekly IcoSema compared to its components, icodec and semaglutide, as well as daily basal-bolus insulin therapy in type 2 diabetes. Methods: Randomized controlled trials (RCTs) of IcoSema in type 2 diabetes were identified through a thorough search of electronic databases. Coprimary outcomes were changes in glycated hemoglobin (HbA1c) and body weight. Meta-analyses were conducted using the RevMan web program with a random-effects model, showing results as mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CIs). Results: Three low-bias RCTs with 2653 subjects were included. IcoSema outperformed the control arm in lowering HbA1c (MD -0.39%, 95% CI [-0.71, -0.07], Conclusions: IcoSema offers better glycemic control and less hypoglycemia risk than controls, with comparable safety for serious AEs. More RCTs involving diverse populations are needed to improve clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.